title: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
abstract: OBJECTIVE
  To determine the place of single-agent paclitaxel compared with nonanthracycline combination chemotherapy as front-line therapy in metastatic breast cancer.
  
  
  METHODS
  Patients with previously untreated metastatic breast cancer were randomized to receive either paclitaxel 200 mg/m(2) intravenously (IV) over 3 hours for eight cycles (24 weeks) or standard cyclophosphamide 100 mg/m(2)/d orally on days 1 to 14, methotrexate 40 mg/m(2) IV on days 1 and 8, fluorouracil 600 mg/m(2) IV on days 1 and 8, and prednisone 40 mg/m(2)/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin recommended as second-line therapy.
  
  
  RESULTS
  A total of 209 eligible patients were randomized with a median survival duration of 17.3 months for paclitaxel and 13.9 months for CMFP. Multivariate analysis showed that patients who received paclitaxel survived significantly longer than those who received CMFP (P =.025). Paclitaxel produced significantly less severe leukopenia, thrombocytopenia, mucositis, documented infections (all P <.001), nausea or vomiting (P =.003), and fever without documented infection (P =.007), and less hospitalization for febrile neutropenia than did CMFP (P =.001). Alopecia, peripheral neuropathy, and myalgia or arthralgia were more severe with paclitaxel (all P <.0001). Overall, quality of life was similar for both treatments (P > = .07).
  
  
  CONCLUSIONS
  Initial paclitaxel was associated with significantly less myelosuppression and fewer infections, with longer survival and similar quality of life and control of metastatic breast cancer compared with CMFP.
authors.affiliation: Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia. Taxol Investigational Trials Group.
authors.forename: J F
authors.initials: JF
authors.lastname: Bishop
authors.forename: J
authors.initials: J
authors.lastname: Dewar
authors.forename: G C
authors.initials: GC
authors.lastname: Toner
authors.forename: J
authors.initials: J
authors.lastname: Smith
authors.forename: M H
authors.initials: MH
authors.lastname: Tattersall
authors.forename: I N
authors.initials: IN
authors.lastname: Olver
authors.forename: S
authors.initials: S
authors.lastname: Ackland
authors.forename: I
authors.initials: I
authors.lastname: Kennedy
authors.forename: D
authors.initials: D
authors.lastname: Goldstein
authors.forename: H
authors.initials: H
authors.lastname: Gurney
authors.forename: E
authors.initials: E
authors.lastname: Walpole
authors.forename: J
authors.initials: J
authors.lastname: Levi
authors.forename: J
authors.initials: J
authors.lastname: Stephenson
authors.forename: R
authors.initials: R
authors.lastname: Canetta
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000556:secondary; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life
chemical_list: D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate